We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Zika Vaccine Protects without Inducing Antibody Production

By LabMedica International staff writers
Posted on 02 Jan 2019
Print article
Image: A digitally colorized transmission electron microscopic (TEM) image of Zika virus. Virus particles, colored blue, are 40 nanometers in diameter, with an outer envelope and an inner dense core (Photo courtesy of the CDC).
Image: A digitally colorized transmission electron microscopic (TEM) image of Zika virus. Virus particles, colored blue, are 40 nanometers in diameter, with an outer envelope and an inner dense core (Photo courtesy of the CDC).
A novel vaccine against Zika virus infection, which was successfully tested in mouse models, is based on the delivery of genes for Zika virus structural proteins via attenuated adenovirus vectors.

Zika virus (ZIKV), against which there are no approved vaccines, is a major public health concern due to the risk of congenital Zika syndrome in developing fetuses and Guillain-Barre syndrome in adults. Previous studies have shown that due to antibody-dependent enhancement (ADE) of disease, antibodies against Zika virus can worsen Dengue virus infection.

In an attempt to circumvent the ADE problem, investigators at the University of Nebraska, Lincoln (USA) developed two adenovirus (Ad) vectored Zika virus vaccines by inserting a ZIKV prM-E gene expression cassette into human Ad types 4 (Ad4-prM-E) and 5 (Ad5-prM-E). Adenoviruses are safe and highly immunogenic vaccine vectors capable of inducing lasting humoral and cellular immune responses.

Results published in the December 20, 2018, online edition of the journal Scientific Reports revealed that Ad5-prM-E vaccination induced both an anti-ZIKV antibody and T-cell responses whereas Ad4-prM-E vaccination only induced a T-cell response. In a highly lethal challenge in interferon receptor knockout mice, 80% of Ad5 vaccinated animals and 33% of Ad4 vaccinated animals survived a lethal ZIKV challenge, whereas no animals in the sham vaccinated control group survived.

In an infection model utilizing immunocompetent C57BL/6 mice that were immunized and then treated with a blocking anti-IFNAR-1 antibody immediately before ZIKV challenge, 100% of Ad4-prM-E and Ad5-prM-E vaccinated mice survived.

These results showed that Ad4-prM-E vaccination was protective without the development of detectable anti-ZIKV antibodies. Overall, the protection seen in these highly lethal mouse models demonstrated the efficacy of Ad vectored vaccines for use against ZIKV.

"If you have immunity to one of these viruses and get infected by a second one, the illness can be much worse," said senior author Dr. Eric Weaver, assistant professor of biological sciences at the University of Nebraska, Lincoln. "The body makes the wrong immune response."

"To our knowledge, this is the first report of a vaccine that uses the prM-E genes of Zika virus to induce protective immunity without inducing anti-Zika virus antibodies," said Dr. Weaver. "The lack of antibodies may very well circumvent the potential risks of ADE resulting in an effective and safer vaccine than those currently in clinical trials. We hope that we can produce a safer vaccine. If we can figure out the mechanism, we might be able to apply it to other vaccine strategies."

Related Links:
University of Nebraska, Lincoln

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Reagent Reservoirs
Reagent Reservoirs

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.